Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2012 1
2014 2
2015 3
2016 3
2017 3
2018 6
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

18 results
Results by year
Filters applied: . Clear all
Page 1
Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins.
Mazor R, King EM, Pastan I. Mazor R, et al. Am J Pathol. 2018 Aug;188(8):1736-1743. doi: 10.1016/j.ajpath.2018.04.016. Epub 2018 Jun 2. Am J Pathol. 2018. PMID: 29870741 Free PMC article. Review.
Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1.
Mazor R, King E, Pastan I. Mazor R, et al. Cell Immunol. 2018 Dec;334:38-41. doi: 10.1016/j.cellimm.2018.08.016. Epub 2018 Aug 28. Cell Immunol. 2018. PMID: 30213644 Free PMC article.
Immunogenicity of therapeutic recombinant immunotoxins.
Mazor R, Onda M, Pastan I. Mazor R, et al. Immunol Rev. 2016 Mar;270(1):152-64. doi: 10.1111/imr.12390. Immunol Rev. 2016. PMID: 26864110 Free PMC article. Review.
Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity.
Mazor R, King EM, Onda M, Cuburu N, Addissie S, Crown D, Liu XF, Kishimoto TK, Pastan I. Mazor R, et al. Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E733-E742. doi: 10.1073/pnas.1717063115. Epub 2018 Jan 8. Proc Natl Acad Sci U S A. 2018. PMID: 29311317 Free PMC article. Review.
Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin.
King EM, Mazor R, Çuburu N, Pastan I. King EM, et al. Among authors: mazor r. J Immunol. 2018 Mar 15;200(6):2038-2045. doi: 10.4049/jimmunol.1701430. Epub 2018 Feb 5. J Immunol. 2018. PMID: 29431691 Free PMC article.
Improving the In Vivo Efficacy of an Anti-Tac (CD25) Immunotoxin by Pseudomonas Exotoxin A Domain II Engineering.
Kaplan G, Mazor R, Lee F, Jang Y, Leshem Y, Pastan I. Kaplan G, et al. Among authors: mazor r. Mol Cancer Ther. 2018 Jul;17(7):1486-1493. doi: 10.1158/1535-7163.MCT-17-1041. Epub 2018 Apr 25. Mol Cancer Ther. 2018. PMID: 29695631 Free PMC article.
SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors.
Leshem Y, King EM, Mazor R, Reiter Y, Pastan I. Leshem Y, et al. Among authors: mazor r. Toxins (Basel). 2018 Nov 14;10(11):470. doi: 10.3390/toxins10110470. Toxins (Basel). 2018. PMID: 30441807 Free PMC article.
Role of HLA-DP in the Presentation of Epitopes from the Truncated Bacterial PE38 Immunotoxin.
Mazor R, Addissie S, Jang Y, Tai CH, Rose J, Hakim F, Pastan I. Mazor R, et al. AAPS J. 2017 Jan;19(1):117-129. doi: 10.1208/s12248-016-9986-y. Epub 2016 Oct 27. AAPS J. 2017. PMID: 27796910
Removing T-cell epitopes with computational protein design.
King C, Garza EN, Mazor R, Linehan JL, Pastan I, Pepper M, Baker D. King C, et al. Among authors: mazor r. Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):8577-82. doi: 10.1073/pnas.1321126111. Epub 2014 May 19. Proc Natl Acad Sci U S A. 2014. PMID: 24843166 Free PMC article.
Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo.
Mazor R, Crown D, Addissie S, Jang Y, Kaplan G, Pastan I. Mazor R, et al. Cell Mol Immunol. 2017 May;14(5):432-442. doi: 10.1038/cmi.2015.91. Epub 2015 Oct 19. Cell Mol Immunol. 2017. PMID: 26477977 Free PMC article.
18 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page